Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Transaction Date: July 14, 2016.
- Price: £16.6781 per share.
- Volume: 595.425 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine acquisition of shares by a senior executive following the dividend payment date of July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of a specific insider transaction.
Investor Verification Points
- Verify the identity of the PDMR: Mr. S A Hussain, President, Global Pharmaceuticals.
- Confirm the transaction was an initial notification of share acquisition via dividend re-investment.
- Note that this filing does not contain quarterly or annual financial performance data.